Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic
Authors:
- Désirée E. S. Larenas-LinnemannDLDésirée E. S. Larenas-Linnemann
- Claudio A. S. ParisiCPClaudio A. S. Parisi
- Ricardo Cardona-VillaRCRicardo Cardona-Villa
- Ivan Cherrez-OjedaICIvan Cherrez-Ojeda
- Annia CherrezACAnnia Cherrez
- Luis Felipe EnsinaLELuis Felipe Ensina
- Elizabeth GarciaEGElizabeth Garcia
- Mónica Rodríguez-GonzálezMRMónica Rodríguez-González
- Jorge Mario Sánchez CaraballoJCJorge Mario Sánchez Caraballo
- 9 May 2018
- journal article
- review article
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 18 (5) , 33
Abstract
Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017–February 2018.Keywords
This publication has 61 references indexed in Scilit:
- Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life ExperienceInternational Archives of Allergy and Immunology, 2016
- Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trialAllergy, 2016
- Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experienceAnnals of Allergy, Asthma & Immunology, 2015
- The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancyJournal of Allergy and Clinical Immunology, 2015
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudyJournal of Investigative Dermatology, 2015
- Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabJournal of Allergy and Clinical Immunology, 2014
- Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulationJournal of Allergy and Clinical Immunology, 2013
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Omalizumab and the risk of malignancy: Results from a pooled analysisJournal of Allergy and Clinical Immunology, 2012